NCT02601417

Brief Summary

Acute cholangitis with obstructive jaundice is a condition which needs biliary drainage and appropriate antibiotics. Bile culture is an optional laboratory test according to 2013, 2018 Tokyo guideline, but the clinical significance is yet unproven. And its results might indicate less information of the true pathogen regarding normal flora. Previous study conducted at our institute found drug-resistant pathogens identified in bile culture had no impact on the outcome. So the investigators are conducting a multicenter randomized controlled trial comparing groups which considers both blood and bile culture as control and which considers only blood culture as trial group in order to prove bile culture provides no additional helpful clinical information.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
440

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Aug 2015

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 27, 2015

Completed
Same day until next milestone

Study Start

First participant enrolled

August 27, 2015

Completed
3 months until next milestone

First Posted

Study publicly available on registry

November 10, 2015

Completed
8.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 20, 2024

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 30, 2024

Completed
Last Updated

May 30, 2024

Status Verified

May 1, 2024

Enrollment Period

8.6 years

First QC Date

August 27, 2015

Last Update Submit

May 23, 2024

Conditions

Keywords

CholangitisBile culturepercutaneous transhepatic biliary drainage

Outcome Measures

Primary Outcomes (1)

  • Organ Failure

    Shock, AKI, altered mentality, Acute respiratory distress

    during hospitalization and empirical antibiotic administration. (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months)

Secondary Outcomes (3)

  • Hospital days

    through study completion, an average of 1 month

  • Re-intervention for biliary drainage

    through study completion, an average of 1 month

  • Mortality

    through study completion, an average of 1 month

Study Arms (2)

Antibiotics change is based on both blood and bile cultures

NO INTERVENTION

Empirical antibiotic therapy was initially conducted for patients. In the control group, the initial antibiotic regimen was maintained if both blood and bile cultures were negative or if all identified organisms were sensitive to empirical treatment. However, the empirical antibiotics were switched to appropriate antibiotics considering the results from blood and bile cultures if any organism demonstrated resistance. Following antibiotic modification in the experimental and control groups, additional biliary drainage procedures (ERCP or PTBD) were performed for considering ineffective drainage on the discretion of physicians.

Antibiotics change is based only on the blood culture

EXPERIMENTAL

Empirical antibiotic therapy was initially conducted for patients. In experimental group, the antibiotic therapy was modified based only on the blood culture findings, where the blood cultures revealed insensitive organisms with the resistance to empirical antibiotics. The bile specimens from these patients were also obtained and cultured, but their results were not considered in the decision-making for antibiotic selection in the experimental group. Following antibiotic modification in the experimental and control groups, additional biliary drainage procedures (ERCP or PTBD) were performed for considering ineffective drainage on the discretion of physicians.

Other: Ignoring result of bile culture

Interventions

the antibiotic therapy was modified based only on the blood culture findings, where the blood cultures revealed insensitive organisms with the resistance to empirical antibiotics. The bile specimens from these patients were also obtained and cultured, but their results were not considered in the decision-making for antibiotic selection in the experimental group

Antibiotics change is based only on the blood culture

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • (1) patients aged ≥20 years with suspected or confirmed acute cholangitis according to the 2013 and 2018 Tokyo guidelines

You may not qualify if:

  • inability to provide informed consent
  • no evidence of acute cholangitis diagnostics as per the guidelines
  • development of organ failure before random allocation or organ failure by non-cholangitis causes
  • undergoing bile culture tests after the onset of organ failure
  • failure to have bile or blood culture tests
  • patients who were already administered antibiotics for other conditions
  • unsuccessful PTBD insertion
  • failure to achieve complete bile drainage via PTBD

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Seoul National University Hospital

Seoul, 110-744, South Korea

Location

MeSH Terms

Conditions

Cholangitis

Condition Hierarchy (Ancestors)

Bile Duct DiseasesBiliary Tract DiseasesDigestive System Diseases

Study Officials

  • Sang Hyub Lee, MD. PhD.

    Department of internal medicine and liver research institute, Seoul national university hospital, Seoul, Korea

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

August 27, 2015

First Posted

November 10, 2015

Study Start

August 27, 2015

Primary Completion

March 20, 2024

Study Completion

July 30, 2024

Last Updated

May 30, 2024

Record last verified: 2024-05

Locations